Biogenesis of p53 Involves Cotranslational Dimerization of Monomers and Posttranslational Dimerization of Dimers

Precisely how mutant p53 exerts a dominant negative effect over wild type p53 has been an enigma. To understand how wild type and mutant p53 form hetero-oligomers, we studied p53 biogenesis in vitro. We show here that p53 dimers are formed cotranslationally (on the polysome), whereas tetramers are formed posttranslationally (by the dimerization of dimers in solution). Coexpression of wild type and mutant p53 therefore results in 50% of the p53 generated being heterotetramers comprised of a single species: wild type dimer/mutant dimer. Using hot spot mutants of p53 and a variety of natural target sites, we show that all wild type/mutant heterotetramers manifest impaired DNA binding activity. This impairment is not due to the mutant dimeric subunit inhibiting association of the complex with DNA but rather due to the lack of significant contribution (positive cooperativity) from the mutant partner. For all heterotetramers, bias in binding is particularly pronounced against those sequences in genes responsible for apoptosis rather than cell growth arrest. These results explain the molecular basis of p53 dominant negative effect and suggest a functional role in the regulation of p53 tetramerization.

[1]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[2]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[3]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[4]  A. Levine,et al.  The p53 protein and its interactions with the oncogene products of the small DNA tumor viruses. , 1990, Virology.

[5]  W. Cavenee,et al.  Mechanisms of p53 loss in human sarcomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Milner,et al.  Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation , 1991, Cell.

[7]  J. Marks,et al.  Maintenance of p53 alterations throughout breast cancer progression. , 1991, Cancer research.

[8]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[9]  C. Theillet,et al.  p53 mutations occur in aggressive breast cancer. , 1992, Cancer research.

[10]  K. Kinzler,et al.  Definition of a consensus binding site for p53 , 1992, Nature Genetics.

[11]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[12]  E. Shaulian,et al.  Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding , 1992, Molecular and cellular biology.

[13]  P. Friedman,et al.  Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. , 1992, Genes & development.

[14]  A. Chumakov,et al.  Analysis of p53 transactivation through high-affinity binding sites. , 1993, Oncogene.

[15]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[16]  L. Donehower,et al.  Spontaneous and carcinogen–induced tumorigenesis in p53–deficient mice , 1993, Nature Genetics.

[17]  D. Malkin,et al.  p53 and the Li-Fraumeni syndrome. , 1993, Cancer genetics and cytogenetics.

[18]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[19]  A. Gronenborn,et al.  High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. , 1994, Science.

[20]  A. Chumakov,et al.  Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. , 1994, Oncogene.

[21]  S. Friend,et al.  Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype. , 1994, Cancer research.

[22]  A. Chumakov,et al.  Mutant p53 proteins behave in a dominant, negative fashion in vivo. , 1994, Anticancer research.

[23]  C. Arrowsmith,et al.  Solution structure of the tetrameric minimum transforming domain of p53 , 1995, Nature Structural Biology.

[24]  D. Beach,et al.  Cyclin G is a transcriptional target of the p53 tumor suppressor protein. , 1994, The EMBO journal.

[25]  S. Velasco-Miguel,et al.  Induction of the growth inhibitor IGF-binding protein 3 by p53 , 1995, Nature.

[26]  G. Marius Clore,et al.  Refined solution structure of the oligomerization domain of the tumour suppressor p53 , 1995, Nature Structural Biology.

[27]  T. Halazonetis,et al.  The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. , 1995, The EMBO journal.

[28]  J. Milner,et al.  Specific DNA binding by different classes of human p53 mutants. , 1995, Oncogene.

[29]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[30]  N. Pavletich,et al.  Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms , 1995, Science.

[31]  M. Oren,et al.  A functional p53-responsive intronic promoter is contained within the human mdm2 gene. , 1995, Nucleic acids research.

[32]  Thierry Soussi,et al.  Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation , 1996, Nucleic Acids Res..

[33]  J. Heighway,et al.  No defect in G1/S cell cycle arrest in irradiated Li-Fraumeni lymphoblastoid cell lines. , 1996, British Journal of Cancer.

[34]  M. Coffey,et al.  Co‐translational trimerization of the reovirus cell attachment protein. , 1996, The EMBO journal.

[35]  T. Halazonetis,et al.  An engineered four-stranded coiled coil substitutes for the tetramerization domain of wild-type p53 and alleviates transdominant inhibition by tumor-derived p53 mutants. , 1996, Cancer research.

[36]  H. Sakamoto,et al.  Effect of Phosphorylation on Tetramerization of the Tumor Suppressor Protein p53 , 1997, Journal of protein chemistry.

[37]  M. Grütter,et al.  In vitro structure-function analysis of the beta-strand 326-333 of human p53. , 1997, Journal of molecular biology.

[38]  K. Kinzler,et al.  14-3-3σ Is a p53-Regulated Inhibitor of G2/M Progression , 1997 .

[39]  H. Sakamoto,et al.  Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. , 1997, Biochemistry.

[40]  D. Evans,et al.  A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li – Fraumeni patients carrying a mutation to the TP53 gene , 1997, Oncogene.

[41]  P. Chène.  In vitro analysis of the dominant negative effect of p53 mutants. , 1998, Journal of molecular biology.

[42]  K. McLure,et al.  How p53 binds DNA as a tetramer , 1998, The EMBO journal.

[43]  D. Pinkel,et al.  Retention of wild‐type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation , 1998, The EMBO journal.

[44]  D. Israeli,et al.  p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.

[45]  A. Hengstermann,et al.  Activation of p53 by conjugation to the ubiquitin‐like protein SUMO‐1 , 1999, The EMBO journal.

[46]  K. Roemer.  Mutant p53: Gain-of-Function Oncoproteins and Wild-Type p53 Inactivators , 1999, Biological chemistry.

[47]  D. Troyer,et al.  Disruption of functions of wild-type p53 by hetero-oligomerization. , 1999, International journal of oncology.

[48]  Alan R. Fersht,et al.  Mechanism of folding and assembly of a small tetrameric protein domain from tumor suppressor p53 , 1999, Nature Structural Biology.

[49]  R. Hay,et al.  SUMO‐1 modification activates the transcriptional response of p53 , 1999, The EMBO journal.

[50]  G. Wahl,et al.  A leucine‐rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking , 1999, The EMBO journal.

[51]  J. Manfredi,et al.  One Mechanism for Cell Type-specific Regulation of thebax Promoter by the Tumor Suppressor p53 Is Dictated by the p53 Response Element* , 1999, The Journal of Biological Chemistry.

[52]  P. Chène,et al.  p53 mutants without a functional tetramerisation domain are not oncogenic. , 1999, Journal of molecular biology.

[53]  K. McLure,et al.  p53 DNA binding can be modulated by factors that alter the conformational equilibrium , 1999, The EMBO journal.

[54]  M. Ljungman.  Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. , 2000, Neoplasia.

[55]  C. Maki,et al.  The MDM2 RING-finger domain is required to promote p53 nuclear export , 2000, Nature Cell Biology.

[56]  Yunping Lin,et al.  Pidd, a new death-domain–containing protein, is induced by p53 and promotes apoptosis , 2000, Nature Genetics.

[57]  M. Blagosklonny,et al.  p53 from complexity to simplicity: mutant p53 stabilization, gain‐of‐function, and dominant‐negative effect , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[58]  E. Stanbridge,et al.  p53 Mutants Have Selective Dominant-Negative Effects on Apoptosis but Not Growth Arrest in Human Cancer Cell Lines , 2000, Molecular and Cellular Biology.

[59]  K. Tsai,et al.  An intact HDM2 RING-finger domain is required for nuclear exclusion of p53 , 2000, Nature Cell Biology.

[60]  T. Hara,et al.  Form of human p53 protein during nuclear transport in Xenopus laevis embryos. , 2000, Experimental cell research.

[61]  M. Kulesz-Martin,et al.  p53 protein at the hub of cellular DNA damage response pathways through sequence-specific and non-sequence-specific DNA binding. , 2001, Carcinogenesis.